Hiroyuki Murota1, Hiroaki Azukizawa2, Ichiro Katayama2. 1. Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 575-0871, Japan. h-murota@derma.med.osaka-u.ac.jp. 2. Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 575-0871, Japan.
Abstract
OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association. Secondary outcomes were quality of life (Skindex-16), itch intensity (Visual Analogue Scale), and patients' subjective disability due to wheal or itch. After the subjects were randomly assigned to groups by block randomization, 10 received Jumihaidokuto, and 11 did not. All subjects had already taken antihistamines. RESULTS: Improvement was significant when comparing the severity score of the Jumihaidokuto group with that of the control group (P<0.01). Skindex-16 values for both groups gradually decreased in the same fashion. CONCLUSION: Concomitant use of Jumihaidokuto with antihistamine was more effective than antihistamine alone in the management of chronic idiopathic urticaria. (Trial Registration No. UMIN000007251).
RCT Entities:
OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association. Secondary outcomes were quality of life (Skindex-16), itch intensity (Visual Analogue Scale), and patients' subjective disability due to wheal or itch. After the subjects were randomly assigned to groups by block randomization, 10 received Jumihaidokuto, and 11 did not. All subjects had already taken antihistamines. RESULTS: Improvement was significant when comparing the severity score of the Jumihaidokuto group with that of the control group (P<0.01). Skindex-16 values for both groups gradually decreased in the same fashion. CONCLUSION: Concomitant use of Jumihaidokuto with antihistamine was more effective than antihistamine alone in the management of chronic idiopathic urticaria. (Trial Registration No. UMIN000007251).
Entities:
Keywords:
Chinese medicine; Jumihaidokuto; Shiwei Baidu Decoction; antihistamine; chronic spontaneous urticaria; crude drug extract; quality of life; severity
Authors: T Zuberbier; W Aberer; R Asero; C Bindslev-Jensen; Z Brzoza; G W Canonica; M K Church; L F Ensina; A Giménez-Arnau; K Godse; M Gonçalo; C Grattan; J Hebert; M Hide; A Kaplan; A Kapp; A H Abdul Latiff; P Mathelier-Fusade; M Metz; S S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; F E R Simons; P Staubach; G Sussman; E Toubi; G A Vena; B Wedi; X J Zhu; A Nast; M Maurer Journal: Allergy Date: 2014-07 Impact factor: 13.146
Authors: H Zhong; Z Song; W Chen; H Li; L He; T Gao; H Fang; Z Guo; J Xv; B Yu; X Gao; H Xie; H Gu; D Luo; X Chen; T Lei; J Gu; B Cheng; Y Duan; A Xv; X Zhu; F Hao Journal: Allergy Date: 2013-12-20 Impact factor: 13.146
Authors: Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell Journal: World Allergy Organ J Date: 2021-06-01 Impact factor: 4.084